Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A PHASE III MULTICENTER RANDOMIZED PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB ANTIPD-L1 ANTIBODY IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST...

to evaluate the efficacy of MPDL3280A nab-paclitaxel compared with placebo nab-paclitaxel as measured by progression-free survival PFS per investigator assessment using Response Evaluation Criteria in Solid Tumors RECIST v11 To evaluate the efficacy of atezolizumab nab-paclitaxel compared with placebo nab-paclitaxel as measured by overall survival OS

FieldValue
Modified
2019-12-23
Release Date
2018-07-20
Identifier
050f8ce6-a9fd-454c-a278-74893b5fbc78
License
Public Access Level
Public